Cancer treatment company Biontech raised $325m round backed by Fidelity. The company forms part of the hopeful oncology and cancer treatment subsector of life sciences which has seen much growth and in corporate backing in recent years.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Rosalind Franklin University has kicked off a bioscience incubator by welcoming its first two residents, while also announcing the appointment of Rosalind Franklin as its president and CEO.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The AI-powered drug discovery platform received commitments from Echo Health Ventures, Amgen Ventures, Alexandria Venture Investments and Celgene in the Cigna-led round.

Casi Pharmaceuticals took part in drug developer Juventas' $14.5m series A-plus round after licensing the latter's Car T-cell drug candidate for haematological malignancies last month.

Fidelity Management & Research has led a $325m series B round for Biontech, a spinout of Johannes Gutenberg University Mainz whose backers also include Sanofi and Pfizer.

Fidelity Management & Research has led a $325m series B round for Biontech, a spinout of Johannes Gutenberg University Mainz whose backers also include Sanofi and Pfizer.

Third Rock contributed to a $100m series C round for UIC's cancer drug developer Revolution that brought its total to $226m.

Haldor Topsøe has returned to participate in a $102m series C round for the cancer treatment developer.